News & Events

2018

  • Aug 14, 2018 Suven’s Income at Rs. 1998 Mn; PAT at Rs. 388 Mn for the quarter ended June 2018 View PDF
  • Aug 08, 2018 Q1 FY19 Schedule of conference call for Investors View PDF
  • Aug 07, 2018 Suven Life Sciences secures Product Patents in Mexico and New Zealand View PDF
  • July 23, 2018 Suven at Alzheimer's Association International Conference (AAIC) in Chicago. View PDF
  • July 16, 2018 Suven Life Sciences secures Product Patents in Europe and South Korea View PDF
  • July 04, 2018 Suven Life Sciences secures Product Patents in India, Singapore, South Korea and Israel View PDF
  • June 12, 2018 Suven Life Sciences secures Product Patents in China and USA View PDF
  • June 08, 2018 Suven Life Sciences is participating and presenting in Jefferies Global Healthcare Conference View PDF
  • June 01, 2018 Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA. View PDF
  • May 29, 2018 Suven Life Sciences secures Product Patents in New Zealand and USA View PDF
  • May 22, 2018 Suven Life Sciences secures Product Patents in New Zealand and Norway View PDF
  • May 17, 2018 Suven Life Sciences secures Product Patents in Australia and Singapore View PDF
  • May 15, 2018 Suven Revenue up by 15%; PAT up by 28% for the year ended March 2018 View PDF
  • May 10, 2018 Q4 FY18 Schedule of conference call for Investors View PDF
  • May 09, 2018 Suven Life Sciences secures Product Patents in Australia, Eurasia and Europe View PDF
  • May 07, 2018 SUVEN’S Pashamylaram’s Unit Successfully completes US FDA Inspection View PDF
  • Apr 24, 2018 USFDA Inspection View PDF
  • Apr 03, 2018 Suven Life Sciences secures a Product Patent in Canada. View PDF
  • Mar 22, 2018 Suven Life Sciences secures Product Patents in Norway, South Korea, and Singapore. View PDF
  • Feb 20, 2018 Suven Life Sciences secures Product Patents in India and South Korea View PDF
  • Jan 31, 2018 Q3 & 9MFY18 Conference Call Transcript View PDF
  • Jan 31, 2018 Suven Life Sciences secures Product Patents in Aripo and South Korea View PDF
  • Jan 30, 2018 Suven Revenue up by 11.85%; PAT up by 15.38% for 9 months ended December’ 2017 View PDF
  • Jan 25, 2018 Q3 FY18 Schedule of conference call for Investors View PDF
  • Jan 18, 2018 Suven Life Sciences secures Product Patents in China and Sri Lanka View PDF

2017

2017

  • Dec 21, 2017 Suven Life Sciences secures Product Patents in Canada and India View PDF
  • Dec 11, 2017 B&K's Investor Conference Emergent India-2017 View PDF
  • Dec 11, 2017 Suven Life Sciences secures Product Patents in India and USA View PDF
  • Dec 06, 2017 Suven Life Sciences secures Product Patents in Eurasia and Norway View PDF
  • Nov 16, 2017 Suven Life secures Product Patents in HongKong, India and USA View PDF
  • Nov 13, 2017 Q2FY18 Earnings Conference Call Transcript View PDF
  • Nov 13, 2017 Suven Life sciences presenting at Neuroscience 2017 at Washington DC View PDF
  • Nov 11,2017 Suven Income at INR 2586 Mn; PAT at INR 613 Mn for the half year ended September 2017 View PDF
  • Oct 18, 2017 Suven Life Sciences secures a Product Patent in Singapore View PDF
  • Oct 13, 2017 Intimation of sad Demise of Director Dr. K.V. Raghavan View PDF
  • Oct 10, 2017 Suven Life Sciences secures a Product Patent in New Zealand View PDF
  • Sep 25, 2017 Suven Life Sciences secures Product Patents in India and Japan View PDF
  • Aug 21, 2017 Suven Life secures a Product Patent in Japan View PDF
  • Aug 17, 2017 Suven Life secures Process Patents in Europe, Japan and New Zealand View PDF
  • Aug 16, 2017 Q1FY18 Earnings Conference Call Transcript View PDF
  • Aug 14, 2017 Suven’s Income at Rs. 1466 Mn; PAT at Rs. 295 Mn for the quarter ended June 2017 View PDF
  • July 21 2017Suven Life secures a Product Patent in Australia View PDF
  • July 14 2017Suven at Alzheimer's Association International Conference (AAIC) in London View PDF
  • July 10 2017Suven Life secures Product Patents in Israel, Macau and South Korea View PDF
  • June 13 2017Suven Life secures a Product Patent in Australia and USA View PDF
  • June 03 2017Suven Team is participating in B&K's Annual Conference 'Trinity India 2017' on June 5, 2017 - Mumbai View PDF
  • May 30 2017Annual Investor Conference "Centrum Corporate Connect - 2017 with fund managers and analysts meet organized in Mumbai by Centrum Broking Limited on 1st & 2nd of June, 2017 View PDF
  • May 25 2017Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor (nAChRs) antagonist for Major Depressive Disorder (MDD) View PDF
  • May 15 2017Q4FY17 Earnings Conference Call Transcript View PDF
  • May 13 2017Suven Revenue up by 9%; PAT up by 23% for the year ended March 2017 View PDF
  • May 11 2017Q4FY17 Schedule of conference call for Investors View PDF
  • March 28 2017Suven Life secures a Product Patents in New Zealand View PDF
  • February 03 2017Suven Team is participating in "ICICI Securities’ Annual Investor Conference 2017" on 6th – 7th February, 2017 View PDF
  • February 02 2017Q3FY17 Earnings Conference Call Transcript View PDF
  • February 01 2017Suven Revenue up by 9.98%; PAT up by 32.77% for 9 months ended December 2016 View PDF
  • January 30 2017Q3FY17 Schedule of Conference Call for Investors View PDF
  • January 30 2017 Suven Life Sciences secures a Product Patent in USA View PDF
  • January 23 2017 Suven Life Sciences secures a Product Patent in Australia View PDF
  • January 11 2017 SuvenInc is presenting at Biotech Showcase™ 2017 on 11th January and attending 35th Annual J.P. Morgan Healthcare Conference at San Francisco View PDF
  • January 03 2017 Suven Life Sciences secures two (2) Product Patents in Eurasia and Norway View PDF

2016

2016

  • December 08 2016 Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE(CTAD) Conference held during December 8-10, 2016 at San Diego, USA View PDF
  • December 07 2016 Suven Life Sciences secures one (1) Product Patent in India View PDF
  • November 25 2016 Q2FY17 Earnings Conference Call Transcript View PDF
  • November 24 2016 Suven Revenue growth at 13.42%; PAT up by 29.15% for the half year ended Sept, 2016 View PDF
  • November 22 2016 Q2FY17 Schedule of Conference Call for Investors View PDF
  • November 22 2016 Suven Life Sciences secures two (2) Product Patents in China and Mexico View PDF
  • November 15 2016 Suven Life Sciences is participating and presenting in “Jefferies London Healthcare Conference “, London View PDF
  • November 14 2016 Suven Life Sciences presenting at Society for Neuroscience (SFN-2016) San Diego. View PDF
  • October 18 2016 Suven Life Sciences secures two (2) Product Patents in Europe and Israel View PDF
  • September 26 2016 Suven Life Sciences secures two (2) Product Patents in India and Japan View PDF
  • September 08 2016 Suven Life secures three (3) Product Patents in Canada, Europe and Hong Kong View PDF
  • August 11 2016 Q1FY17 Earnings Conference Call Transcript View PDF
  • August 10 2016 Q1FY17 Schedule of Conference Call for Investors View PDF
  • August 10 2016 Suven’s Income at Rs. 1377 Mn; PAT at Rs. 326 Mn for the 1st quarter ended June 2016 View PDF
  • August 01 2016 Suven Life secures two (2) Product Patents in Macau and New Zealand View PDF
  • July 25 2016 Suven to Present at Alzheimer's Association International Conference (AAIC) View PDF
  • July 21 2016 SUVEN’S Pashamylaram’s Unit Successfully completes US FDA Inspection View PDF
  • July 12 2016 Suven Life secures two (2) Product Patents in India and South Africa View PDF
  • June 29 2016 Suven Life secures three (3) Product Patents in Europe and Eurasia View PDF
  • June 14 2016 Suven Life Sciences secures two (2) Product Patents in Canada and Hong Kong View PDF
  • June 03 2016 Suven Life Sciences secures two (2) Product Patents in Israel and Mexico View PDF
  • May 31, 2016 Suven Team is participating in "Annual Investors Conference Trinity India-2016" on June 1st View PDF
  • May 30, 2016 Q4FY16 Earnings Conference Call Transcript View PDF
  • May 30, 2016 Q4FY16 Schedule of Conference Call for Investors View PDF
  • May 27, 2016 Suven Revenue up by 49.21%; PAT up by 83.23% for the Fourth quarter ended March 2016 View PDF
  • May 23, 2016 Suven Life Sciences secures 4 (four) Product Patents for their NCE's in Australia, Eurasia, Israel and USA View PDF
  • Apr 04, 2016 Suven to Present at Bio-Europe Spring 2016 conference being held at Stockholm, Sweden. View PDF
  • Mar 14, 2016 Suven Life secures three (3) Product Patents in China, Eurasia and Hong Kong View PDF
  • Mar 09, 2016 Investors Meet on 10th & 11th March, 2016 View PDF
  • Mar 07, 2016 Investor Conference Call on 8th March, 2016 View PDF
  • Feb 19, 2016 Suven Life Sciences secures two (2) Product Patents in Australia and Canada View PDF
  • Feb 15, 2016 Q3FY16 Earnings Conference Call Transcript View PDF
  • Feb 12, 2016 Suven Revenue down by 4.96%; PAT down by 28.34% for the Third quarter ended December, 2015 View PDF
  • January 11, 2016 Suven Inc is presenting at Biotech Showcase™ 2016 and participating in the 34th Annual J.P. Morgan Healthcare Conference during January 11th to 14th,2016 at San Francisco View PDF
  • January 05, 2016 Suven Life Sciences secures three (3) Product Patents in Canada, ARIPO and South Korea View PDF

2015

2015

  • December 29, 2015 Suven Life Sciences secures Two (2) Product Patents in Europe and Macau View PDF
  • December 23, 2015 Suven Life Sciences secures 7 (seven) Product Patents for their NCE’s in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea View PDF
  • December 14, 2015 Suven Life Sciences at Centrum Pharma Day Mumbai for analysts’ meet View PDF
  • December 11, 2015 Suven Life secures four (4) Product Patents in Eurasia, Europe, Israel and Macau View PDF
  • December 07, 2015 Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s Disease View PDF
  • November 16, 2015 Q2FY16 Earnings Conference Call Transcript View PDF
  • November 10, 2015 Suven Revenue growth at 15.55%; PAT up by 22.23% for the Second quarter ended Sept, 2015 View PDF
  • November 05, 2015 Suven to Present at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during NOVEMBER 5-7, 2015 at Barcelona, Spain View PDF
  • November 02, 2015 Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in Munich, Germany View PDF
  • October 19, 2015 Suven Life Sciences at Society for Neuroscience (SFN-2015) Chicago. Presenting data on several of their NCE's. View PDF
  • October 13, 2015 Suven Life Sciences secures 5 (five) Product Patents for their NCE’s in Australia, China, Europe, South Korea and USA View PDF
  • October 01, 2015 Suven Life secures three (3) Product Patents in New Zealand, Singapore and USA View PDF
  • September 28, 2015 Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” View PDF
  • September 16, 2015 Suven Life Sciences secures Three (3) Product Patents in Canada and China View PDF
  • September 10, 2015 Suven Life Sciences secures five (5) Product Patents in China, Israel, Mexico, Singapore and Sri Lanka View PDF
  • September 02, 2015 SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-IND 126099 View PDF
  • August 17, 2015 Q1FY16 Earnings Conference Call Transcript View PDF
  • August 14, 2015 Suven’s Income lower by 7.35%; PAT increase by 19.36% for the quarter ended June 2015 View PDF
  • July 17, 2015 Suven to Present at Alzheimer's Association International Conference (AAIC) View PDF
  • July 13, 2015 Suven Life Sciences secures 4 (four) Product Patents for their NCE’s in China, Mexico and South Africa View PDF
  • June 30, 2015 Suven Life Sciences secures Three (3) Product Patents in Israel, Japan and South Africa View PDF
  • June 16, 2015 Suven Life secures Three (3) Product Patents in Israel, Macau and USA View PDF
  • May 27, 2015 Q4 FY15 Conference Call Transcript View PDF
  • May 26, 2015 Suven’s Income increased by 3% and PAT lower by 25% for the year ended March 2015 View PDF
  • May 22, 2015 Suven Life secures One (1) Product Patent each in Mexico and Singapore View PDF
  • May 13, 2015 Suven Life secures Two (2) Product Patents in Europe and Hong kong View PDF
  • April 24, 2015 Suven Life secures Five (5) Product Patents for their NCEs in Australia, Europe, Hong kong, Israel and Norway View PDF
  • April 13, 2015 Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031 View PDF
  • Mar 24, 2015 Suven Life secures Three (3) Product Patents for their NCEs in Canada, Japan and Korea View PDF
  • Mar 16, 2015 Suven Life Sciences secures 2 (two) Product Patents for their NCE’s through New mechanism of action – H3 Inverse Agonist in USA & New Zealand View PDF
  • Mar 09, 2015 Suven Life secures One (1) Product Patent each in Eurasia and Israel View PDF
  • Feb 16, 2015 Suven Life Sciences secures 4 (four) Product Patents for their NCE’s through New mechanism of action – H3 Inverse Agonist in Australia, Canada, Japan and New Zealand View PDF
  • Feb 13, 2015 Q3 FY15 Conference Call Transcript View PDF
  • Feb 10, 2015 Suven Revenue growth at 9% while PAT is down by 11.55% for the 3rd Quarter ended Dec 2014 View PDF
  • Jan 20, 2015 Suven Life secures One (1) Product Patent each in Australia & Hong Kong, two (2) product patents from Japan View PDF

2014

2014

  • Dec 30, 2014 Suven Life secures three (3) Product Patents in Eurasia, Japan, and Mexico View PDF
  • Dec 30, 2014 Suven Life secures three (3) Product Patents in Eurasia, Japan, and Mexico View PDF
  • Dec 12, 2014 Suven Life secures (5) Product Patents for their NCEs in Israel, Japan, China and New Zealand View PDF
  • Dec 03, 2014 Suven Life Sciences Limited Raises INR 200 Cr Through a Qualified Institutions Placement (QIP) View PDF
  • Nov 17, 2014 Q2 FY15 Conference Call Transcript View PDF
  • Nov 14, 2014 Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended Sept, 2014 View PDF
  • Nov 3, 2014 SUVN-G3031 for Cognition in Alzheimer’s Disease commenced Phase 1 Clinical Trial in USA under US-IND 123179 View PDF
  • Oct 13, 2014 Suven Life secures One (1) Product Patent in South Korea and one (1) from USA View PDF
  • Oct 07, 2014 Suven Life Sciences is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014. View PDF
  • Sep 23, 2014 Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing. View PDF
  • Sep 03, 2014 Suven Life Sciences secures (3) Product Patents for their NCEs in South Korea, China and Canada View PDF
  • Aug 13, 2014 Q1 FY15 Conference Call Transcript View PDF
  • Aug 12, 2014 Suven achieved a PAT of Rs.34.73 Crores for first Qtr of 2014-15, an increase of 16.68% compared to same quarter of previous year View PDF
  • Aug 06, 2014 Suven Life secures (2) Product Patents for their NCEs in Australia and Eurasia View PDF
  • July 11, 2014 Suven to Present at Alzheimer's Association International Conference (AAIC) View PDF
  • June 04, 2014 Suven Life secures One (1) Product Patent in USA View PDF
  • May 26, 2014 Suven Investor/Analyst Conference Call Transcript View PDF
  • May 22, 2014 Suven’s PAT up by 367% for the year ended March 2014 & proposed regular and one time special silver jubilee year dividend aggregating to 250% View PDF
  • May 19, 2014 Suven Life secures (3) Product Patents in Australia, South Korea and China View PDF
  • April 10, 2014 Suven Life secures (2) Product Patents for their NCEs in Canada and Hong Kong View PDF
  • Mar 26, 2014 Suven Life secures (2) Product Patents for their NCEs in USA View PDF
  • Mar 04, 2014 Suven grants an exclusive license & right to distribute its Malathion Lotion in USA, CANADA and MEXICO to Taro Pharmaceuticals View PDF
  • Feb 06, 2014 Suven Investor/Analyst Conference Call Transcript View PDF
  • Feb 14, 2014 Suven Life secures (2) Product Patents for their NCEs in New Zealand View PDF
  • Feb 04, 2014 Suven Q3 PAT up by 370% to Rs.36.43 Cr View PDF
  • Jan 31, 2014 Suven Life secures (3) Product Patents for their NCEs in Canada, China and India View PDF
  • Jan 22, 2014 SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCE View PDF
  • Jan 09, 2014 Suven Life secures three (3) Product Patents for their NCEs in Australia, Sri Lanka and South Korea View PDF

2013

2013

  • Nov 13, 2013 Suven Investor/Analyst Conference Call Transcript View PDF
  • Nov 11, 2013 Suven Q2 PAT up by 602% to Rs.45.55 Cr View PDF
  • Nov 08, 2013 Suven Life Sciences presenting the positive pharmacology data of 4 NCEs at Society for Neuroscience (SFN-2013) Annual Meeting at San Diego, USA View PDF
  • Nov 05, 2013 Suven Life secures two (2) Product Patents for their NCEs in USA and Japan View PDF
  • Sep 25, 2013 Suven Life secures three (3) Product Patents for their NCEs in New Zealand, Singapore and South Korea View PDF
  • Aug 13,2013 Suven Q1 PAT up by 274% to Rs.29.77 Cr View PDF
  • Aug 08,2013 Suven Life secures two (2) Product Patents for their NCEs in Europe View PDF
  • July 12,2013 Suven to Present at Alzheimer's Association International Conference (AAIC) View PDF
  • June 28,2013 Suven Life Sciences secures two (2) Product Patents for their NCEs in Japan and USA View PDF
  • May 14, 2013 Suven‘s PAT up by 115% for the year ended Mar 2013 View PDF
  • May 10, 2013 Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia. View PDF
  • April 17, 2013 Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New Zealand View PDF
  • Feb 12, 2013 Suven‘s PAT up by 500 % for the quater ended Dec 2012 View PDF

2012

2012

  • Dec 31, 2012 Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada. View PDF
  • Dec 13, 2012 Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea View PDF
  • Nov 15, 2012 Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012 View PDF
  • Oct 04, 2012 Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award” View PDF
  • Aug 14, 2012 Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012 View PDF
  • Aug 09, 2012 Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New Zealand. View PDF
  • July 13, 2012 Suven to Present at Alzheimer's Association International Conference (AAIC) View PDF
  • May Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and Eurasia View PDF
  • May 04, 2012 Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012 View PDF
  • April 03, 2012 Suven Life Sciences secures 4 Product Patents for their NCEs in China and Korea View PDF
  • Feb 07, 2012 Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA View PDF
  • Jan 31, 2012 Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011 View PDF

2011

2011

  • Dec 08, 2011 Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and Canada View PDF
  • Nov 14, 2011 Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-2011) Annual Meeting at Washington DC, USA View PDF
  • Nov 1, 2011 Suven‘s revenue up by 31% and spends 18% of revenue on R&D; View PDF
  • Oct4, 2011 Suven Life Sciences bags Pharmexcil’s Gold “Patent Award” View PDF
  • Sep 22, 2011 Suven Participating at 4th CNS Partnering & Deal Making Conference in USA View PDF
  • Sep 5, 2011 Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New Zealand View PDF
  • Aug 18, 2011 Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the world View PDF
  • Aug 13, 2011 Suven‘s revenue up by 24% and spends 17% of revenue on R&D View PDF
  • July 18, 2011 Suven presenting at International Conference on Alzheimer’s disease (ICAD) View PDF
  • June 20, 2011 Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world View PDF
  • May 30, 2011 Suven Spends 20.5% of Revenue on R&D PAT up by 48.55% for the year ending March 2011 View PDF
  • May 26, 2011 Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the world View PDF
  • May 18, 2011 Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS) View PDF
  • May 09, 2011 Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011” View PDF
  • April 26, 2011 Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world View PDF
  • April 5, 2011 SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCE View PDF
  • Jan 31, 2011 Suven spends 24% of revenue on R&D ;PAT up by 55% for for the 3rd quarter ending Dec 2010 View PDF
  • Jan 11, 2011 Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011 View PDF

2010

2010

  • Dec 30, 2010 Suven Life Sciences secures 2 Product Patents For Their NCEs View PDF
  • Dec 23, 2010 Suven Life Sciences secures 4 Product Patents For Their NCEs View PDF
  • Nov 12, 2010 Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting (SFN-2010) at San Diego, USA View PDF
  • Oct 27 2010 Suven spends 21% of revenue on R&D PAT up by 23% for the half year View PDF
  • Sep 27 2010 Suven Life Sciences bags Pharmexcil's Gold “Patent Award” View PDF
  • Sep 21 2010 Suven Life Sciences secures Two US Patents on NCEs View PDF
  • Sep 8 2010 Suven Secures 8th product patent Both in Australia and Mexico View PDF
  • July 27 2010 Suven spends 22% of revenue on R&D PAT up by 58% for the 1st Quarter View PDF
  • July 12 2010 Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD) View PDF
  • June 16 2010 Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE’s to treat Central Nervous System (CNS) disorders View PDF
  • May 25 2010 Suven’s partnering and fundraising activity at C21 BioVentures™ View PDF
  • May 12 2010 Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCE View PDF
  • May 3 2010 Prof. Syed Hasnain joins Suven as Additional Director View PDF
  • Apr 30 2010 Suven spends 26% of Revenue on R&D for the year ended March 2010 View PDF
  • Apr 28 2010 Suven Life Sciences secures Product Patents from India and New Zealand View PDF
  • Apr 22 2010 Suven Life Sciences secures Three Australian Patents on NCEs View PDF
  • Apr 12 2010 Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE to treat Central Nervous System (CNS) disorders View PDF
  • Mar 29 2010 Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders View PDF
  • Mar 22 2010 Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System (CNS) disorders View PDF
  • Jan 27 2010 Suven spends 34% of Revenue on R&D for the 3rd quarter ending Dec’ 09 View PDF
  • Jan 12 2010 Suven Secures Two product patents in China and Russia View PDF

2009

2009

  • Dec 14 2009 Suven Secures two Product patents from Canadian Intellectual Property Office View PDF
  • Nov 30 2009 Suven Life Sciences secures Three European Patents on NCEs View PDF
  • Oct 31 2009 Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09 View PDF
  • Oct 20 2009 Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2009 at Chicago, USA View PDF
  • Oct 14 2009 Suven’s Clinical Candidate SUVN-502 For Alzheimer’s disease Secures product patents in several Key markets in the world View PDF
  • Sep 14 2009 Suven Life Sciences secures Two US Patents on NCEs View PDF
  • Sep 07 2009 Suven achieves 1st Milestone payment in Drug Discovery collaboration View PDF
  • July 28 2009 Suven’s profit up by 37%, Spends 22% of Revenue on R&D. View PDF
  • July 27 2009 Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer’s disease at ICAD 2009, Vienna, Austria. View PDF
  • May 6 2009 SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE. View PDF
  • Apr 29 2009 Suven’s revenue up by 19%, Spends 22% of Revenue on R&D. View PDF
  • Apr 9 2009 Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland. View PDF
  • Jan 19 2009 Suven’s revenue up by 21%, Spends 24% of Revenue on R&D. View PDF
  • Jan 13 2009 Suven participation at Biotech Showcase 2009. View PDF

2008

2008

  • Nov 18 2008 Suven participation at Bio-Europe 2008. View PDF
  • Nov 11 2008 Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held from 10-12 November 2008 View PDF
  • Oct 31 2008 Suven's net up by 50%, Spends 17% of Revenue on R&D View PDF
  • Oct 13 2008 SUVN-502 data being presented at 16th BioPartnering in London View PDF
  • Sep 29 2008 Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in Switzerland View PDF
  • Sep 25 2008 DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer’s disease View PDF
  • Aug 18 2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride View PDF
  • Aug 4 2008 Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer’s conference, Chicago and Drug Discovery conference, Boston View PDF
  • Jul 25 2008 Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland for Alzheimer’s Disease View PDF
  • Jul 7 2008 Suven Life Sciences Clinical candidate SUVN-502 being presented at International Conference on Alzheimer’s Disease, ICAD-2008 at Chicago, USA View PDF
  • Jun 18 2008 Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s disease View PDF
  • May 27 2008 Suven Life Sciences gets Two product patents for NCEs in Russia and Australia View PDF
  • May 20 2008 Suven Life Sciences gets Two product patents for NCEs in South Africa and China View PDF
  • May 5 2008 Suven's Clinical Candidate SUVN-502 Secures European Product Patent View PDF
  • Apr 26 2008 -Revenue growth at 7.44%, R&D spent at 24.53% of Revenue<br> -17 Product Patents obtained during the qtr globally<br> -Establishes Second CNS Drug Discovery Collaboration with Lilly View PDF
  • Mar 31 2008 Suven Life Sciences gets Two Product patents in Korea and Mexico View PDF
  • Mar 24 2008 Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region) View PDF
  • Mar 12 2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly View PDF
  • Jan 28 2008 Suven Revenue stands flat, R&D spent at 25% of Revenue obtains 2 US, 3 European and 4 Indian Product Patents during the qtr View PDF
  • Jan 23 2008 Suven obtains&nbsp; 2nd Product Patent from US Patent office View PDF

2007

2007

  • Dec 27 2007 Suven obtains 1st Product Patent from US Patent office View PDF
  • Dec 11 2007 Suven presenting at Windhover's Bio/Pharma Partnerships conference in San Francisco View PDF
  • Nov  27 2007 Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases. View PDF
  • Nov 05 2007 -Suven Life Sciences presenting Pre-clinical data of their NCE's at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA View PDF
  • Oct 31 2007 Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs) View PDF
  • Oct 30 2007 Suven's half yearly revenues increase by 10%, R&D spent at 26% of Revenue View PDF
  • Oct 25 2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection View PDF
  • Oct 23 2007 Suven Life Sciences Secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs) View PDF
  • Jul 31 2007 Suven PAT up by 51%;R&D spend at 33% of Revenue View PDF
  • Jul 12 2007 Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 in India to conduct Phase 1 clinical trials View PDF
  • Jul 5 2007 Suven Life Sciences presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia View PDF
  • Jun 11 2007 -Suven's unit III receives US FDA acceptance View PDF
  • Apr 26 2007 Suven yearly revenues increase by 38%, PAT up by 33% ; R&D spend at 24% of Revenue View PDF
  • Jan 29 2007 Suven Income up by 35%, Spends 17% on R&D -Suven shares split from Rs 2 per share to Re. 1 per share and issues bonus shares in the ratio of 1:1 View PDF
  • Jan 1 2007Suven renewed ISO 14001 certification View PDF
  • Jan 1 2007Suven renewed ISO 9001 certification View PDF
  • Jan 1 2007Suven received OHSAS 18001 certification View PDF

2006

2006

  • Sep 20 2006 Suven receives NABL certification View PDF
  • Aug 29 2006 Suven and Lilly Establish Drug Discovery Collaboration View PDF
  • Aug 16 2006 Preclinical Data on Suven’s 5-HT6 antagonists for CNS diseases to be presented at Neuroscience 2006 View PDF
  • Jul 31 2006 SUVEN’s quarterly revenues increase by 60%, PAT up by 51%; R&D spend at 16% of Revenue View PDF

2005

2005

  • Nov 21 2005 Suven Life Sciences presented Pre-clinical data of their NCEs at Society for Neuroscience (SFN) Annual Meeting, Washington DC, USA View PDF
  • Oct 11 2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain. View PDF
  • Oct 03 2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan View PDF

2004

2004

  • Dec 2004 Suven Life Sciences ropes in global contract research industry veteran View PDF
  • Oct 2004 Suven pharma promoter invests $1-m in CRO, data development View PDF
  • Apr 2004 Suven Life Sciences net Income up by 27.76% View PDF
  • Apr 27, 2004 Suven Life income up 10 p.c. View PDF
  • Mar 23, 2004 Suven to set up Rs 100 cr unit in Vizag View PDF
  • Feb 5, 2004 Suven Life Sciences net up 57 percent View PDF
  • Feb 1, 2004 Suven profit up 5% to Rs. 1.91 cr in Q3 View PDF
  • Jan 1, 2004 Suven gets ISO 14001 certification View PDF

2003

2003

  • Dec 18, 2003 Suven Life to raise Rs 27.4 cr through preferential issue Borregaard exits Suven Life Sciences View PDF
  • Dec 5, 2003 Suven board okays merger of subsidiary Suven Life board decides to split shares View PDF
  • Nov 28, 2003 Suven board to consider merger of subsidiarySuven Life Sciences may merge arm with selfSuven plans pref issue, share split, merger of arm View PDF
  • Nov 24, 2003 Suven graduating itself to life sciences player View PDF
  • Oct 23, 2003 The $15 billion bulk drug opportunityCPhI: Downpour of deals View PDF
  • Sep 29, 2003 Venkat Jasti re-elected president of BDMA View PDF
  • Sep 6, 2003 Spurious drugs eating into AP’s export share View PDF
  • Aug 07, 2003 Suven Pharma rechristened Suven Life View PDF
  • Aug 02, 2003 Suven Pharma is Suven Life now View PDF
  • August 01, 2003 Suven Q1 net up 63% at Rs 2.3 cr View PDF
  • Jul 7, 2003 PA fellowship Award View PDF
  • Jun12, 2003 Venkat Jasti asks Govt. & Industry to play pro-active role to tap the potential post-2005 View PDF
  • Jun 2, 2003 Venkat Jasti joins Pharmabiz advisory board View PDF
  • May 20, 2003 SUVEN Pharma acquires assets of New Jersey (USA) based SYNTHON CHIRAGENICS View PDF
  • Apr 26, 2003 SUVEN spent 21 % of its revenue in R & D View PDF
  • Apr 21, 2003 SUVEN eyes discovery research View PDF
  • Mar 25, 2003 Drug discovery boutique set up 3 Indian Pharma form allianceDesi Pharma trio ally for new patent regime Life sciences alliance formed — 3 pharma cos tie up with US firm3 cos. forge alliance with U.S. firm3 drug firms join hands View PDF

2002

2002

  • Dec 24, 2002 SUVEN Pharma sees revenue jump after April 2004 View PDF
  • Oct 18, 2002 SUVEN starts research academySUVEN Pharma to collaborate in promoting the Centre of Excellence in clinical research View PDF
  • Aug 07 , 2002 SUVEN sets the stage for Contract Research in India View PDF
  • Jun 03 , 2002 Speeding up drug discovery View PDF

2001

2001

  • Dec 25, 2001 Pharma sector hopes to have Export Promotion Council soon Andhra Pradesh to set up Pharma City View PDF
  • Dec 24, 2001 After IT and BT, Pharma catches Chandrababu Naidu's eyeForget IT, Pharma is the new mantraPharmaexcilSeperate Export Promotion Council for pharma sector on anvilPharmaexcil likely to be operational View PDF
  • Dec 23, 2001 Pharma City in Vizag View PDF
  • Dec 21, 2001 Vizag's Pharma City to get a booster doseVizag Pharma City Phase-I to be operational by 2003 View PDF
  • Nov 23, 2001 A.P. to attract global majors as healthcare capital View PDF
  • Nov 1, 2001 SUVEN Pharma View PDF